@ARTICLE{10.3389/fcvm.2021.695206, AUTHOR={Omidi, Fatemeh and Hajikhani, Bahareh and Kazemi, Seyyedeh Neda and Tajbakhsh, Ardeshir and Riazi, Sajedeh and Mirsaeidi, Mehdi and Ansari, Ali and Ghanbari Boroujeni, Masoud and Khalili, Farima and Hadadi, Sara and Nasiri, Mohammad Javad}, TITLE={COVID-19 and Cardiomyopathy: A Systematic Review}, JOURNAL={Frontiers in Cardiovascular Medicine}, VOLUME={8}, YEAR={2021}, URL={https://www.frontiersin.org/articles/10.3389/fcvm.2021.695206}, DOI={10.3389/fcvm.2021.695206}, ISSN={2297-055X}, ABSTRACT={Background: Cardiomyopathies (CMPs) due to myocytes involvement are among the leading causes of sudden adolescent death and heart failure. During the COVID-19 pandemic, there are limited data available on cardiac complications in patients with COVID-19, leading to severe outcomes.Methods: We conducted a systematic search in Pubmed/Medline, Web of Science, and Embase databases up to August 2020, for all relevant studies about COVID-19 and CMPs.Results: A total of 29 articles with a total number of 1460 patients were included. Hypertension, diabetes, obesity, hyperlipidemia, and ischemic heart disease were the most reported comorbidities among patients with COVID-19 and cardiomyopathy. In the laboratory findings, 21.47% of patients had increased levels of troponin. Raised D-dimer levels were also reported in all of the patients. Echocardiographic results revealed mild, moderate, and severe Left Ventricular (LV) dysfunction present in 17.13, 11.87, and 10% of patients, respectively.Conclusions: Cardiac injury and CMPs were common conditions in patients with COVID-19. Therefore, it is suggested that cardiac damage be considered in managing patients with COVID-19.} }